HLS Therapeutics Inc. (HLS.TO)
CAD 4.4
(0.92%)
CAD 4.4
(0.92%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -10.34 Million USD | 25.6% |
| 2022 | -13.44 Million USD | -115.38% |
| 2021 | -6.24 Million USD | 44.56% |
| 2020 | -11.25 Million USD | -178.41% |
| 2019 | -4.04 Million USD | -152.93% |
| 2018 | 7.63 Million USD | -67.19% |
| 2017 | 23.28 Million USD | 1954.11% |
| 2016 | -1.25 Million USD | 49.07% |
| 2015 | -2.46 Million USD | -115.25% |
| 2014 | 16.16 Million USD | 29.58% |
| 2013 | 12.47 Million USD | -43.25% |
| 2012 | 21.98 Million USD | 33.57% |
| 2011 | 16.45 Million USD | -6.77% |
| 2010 | 17.65 Million USD | 334.93% |
| 2009 | 4.05 Million USD | -8.73% |
| 2008 | 4.44 Million USD | -63.15% |
| 2007 | 12.06 Million USD | 793.76% |
| 2006 | 1.35 Million USD | 1039.12% |
| 2005 | -143.79 Thousand USD | -114.84% |
| 2004 | 969.1 Thousand USD | -81.49% |
| 2003 | 5.23 Million USD | 49.74% |
| 2002 | 3.49 Million USD | -0.08% |
| 2001 | 3.49 Million USD | 34.96% |
| 2000 | 2.59 Million USD | -34.13% |
| 1999 | 3.93 Million USD | 188.36% |
| 1998 | 1.36 Million USD | -30.25% |
| 1997 | 1.95 Million USD | 88.37% |
| 1996 | 1.03 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -2.02 Million USD | 100.0% |
| 2024 Q1 | -3.33 Million USD | -273.01% |
| 2023 FY | -9.99 Million USD | 25.6% |
| 2023 Q1 | -3.16 Million USD | 22.49% |
| 2023 Q2 | -2.98 Million USD | 5.82% |
| 2023 Q3 | -2.96 Million USD | 0.6% |
| 2023 Q4 | -893 Thousand USD | 69.85% |
| 2022 Q1 | -2.88 Million USD | -20.44% |
| 2022 FY | -13.44 Million USD | -115.38% |
| 2022 Q3 | -2.92 Million USD | 17.45% |
| 2022 Q2 | -3.54 Million USD | -23.15% |
| 2022 Q4 | -4.08 Million USD | -39.36% |
| 2021 Q3 | -336 Thousand USD | 34.12% |
| 2021 Q1 | -3.04 Million USD | 17.81% |
| 2021 FY | -6.24 Million USD | 44.56% |
| 2021 Q2 | -510 Thousand USD | 83.26% |
| 2021 Q4 | -2.39 Million USD | -611.9% |
| 2020 Q3 | -1.75 Million USD | 59.25% |
| 2020 Q4 | -3.7 Million USD | -111.41% |
| 2020 Q2 | -4.3 Million USD | -84.95% |
| 2020 FY | -11.25 Million USD | -178.41% |
| 2020 Q1 | -2.32 Million USD | 21.21% |
| 2019 Q1 | -458 Thousand USD | -117.53% |
| 2019 Q2 | -469 Thousand USD | -2.4% |
| 2019 FY | -4.04 Million USD | -152.93% |
| 2019 Q4 | -2.95 Million USD | -294.13% |
| 2019 Q3 | -749 Thousand USD | -59.7% |
| 2018 Q2 | 2.78 Million USD | 679.27% |
| 2018 FY | 7.63 Million USD | -67.19% |
| 2018 Q4 | 2.61 Million USD | 38.35% |
| 2018 Q3 | 1.88 Million USD | -32.14% |
| 2018 Q1 | 357 Thousand USD | -98.55% |
| 2017 Q1 | -412.42 Thousand USD | -36.19% |
| 2017 FY | 23.28 Million USD | 1954.11% |
| 2017 Q4 | 24.6 Million USD | 5345.14% |
| 2017 Q3 | -469.15 Thousand USD | -19.87% |
| 2017 Q2 | -391.36 Thousand USD | 5.1% |
| 2016 Q3 | -195.47 Thousand USD | 45.61% |
| 2016 FY | -1.25 Million USD | 49.07% |
| 2016 Q2 | -359.41 Thousand USD | 12.14% |
| 2016 Q1 | -409.07 Thousand USD | -212.82% |
| 2016 Q4 | -302.82 Thousand USD | -54.92% |
| 2015 Q2 | -182.06 Thousand USD | 90.2% |
| 2015 Q3 | -412.66 Thousand USD | -126.66% |
| 2015 Q4 | -130.77 Thousand USD | 68.31% |
| 2015 FY | -2.46 Million USD | -115.25% |
| 2015 Q1 | -1.85 Million USD | -130.1% |
| 2014 FY | 16.16 Million USD | 29.58% |
| 2014 Q4 | 6.17 Million USD | 39.79% |
| 2014 Q1 | 3.79 Million USD | 3.77% |
| 2014 Q2 | 1.9 Million USD | -49.7% |
| 2014 Q3 | 4.41 Million USD | 131.31% |
| 2013 Q3 | 3.24 Million USD | 249.06% |
| 2013 Q1 | 4.69 Million USD | -13.33% |
| 2013 FY | 12.47 Million USD | -43.25% |
| 2013 Q4 | 3.65 Million USD | 12.7% |
| 2013 Q2 | 929.51 Thousand USD | -80.18% |
| 2012 Q4 | 5.41 Million USD | -0.98% |
| 2012 FY | 21.98 Million USD | 33.57% |
| 2012 Q3 | 5.46 Million USD | -6.74% |
| 2012 Q2 | 5.85 Million USD | 17.44% |
| 2012 Q1 | 4.98 Million USD | -1.23% |
| 2011 Q1 | 4.99 Million USD | -74.89% |
| 2011 Q2 | 3.78 Million USD | -24.28% |
| 2011 Q3 | 3.19 Million USD | -15.48% |
| 2011 Q4 | 5.05 Million USD | 57.98% |
| 2011 FY | 16.45 Million USD | -6.77% |
| 2010 Q2 | 4.5 Million USD | 45.05% |
| 2010 FY | 17.65 Million USD | 334.93% |
| 2010 Q1 | 3.1 Million USD | 20.72% |
| 2010 Q4 | 19.89 Million USD | 1861.94% |
| 2010 Q3 | -1.12 Million USD | -125.04% |
| 2009 Q3 | -1.38 Million USD | -139.52% |
| 2009 Q2 | 3.51 Million USD | 5309.05% |
| 2009 FY | 4.05 Million USD | -8.73% |
| 2009 Q4 | 2.57 Million USD | 285.48% |
| 2009 Q1 | 64.94 Thousand USD | 104.07% |
| 2008 FY | 4.44 Million USD | -63.15% |
| 2008 Q4 | -1.59 Million USD | -179.92% |
| 2008 Q3 | 1.99 Million USD | -12.09% |
| 2008 Q2 | 2.27 Million USD | 164.19% |
| 2008 Q1 | 859.8 Thousand USD | -69.02% |
| 2007 Q1 | 2.24 Million USD | 1271.9% |
| 2007 FY | 12.06 Million USD | 793.76% |
| 2007 Q4 | 2.77 Million USD | 13.47% |
| 2007 Q3 | 2.44 Million USD | -28.14% |
| 2007 Q2 | 3.4 Million USD | 51.42% |
| 2006 Q1 | 690.51 Thousand USD | 154.76% |
| 2006 Q2 | 391.31 Thousand USD | -43.33% |
| 2006 Q3 | -317.03 Thousand USD | -181.02% |
| 2006 Q4 | -191.8 Thousand USD | 39.5% |
| 2006 FY | 1.35 Million USD | 1039.12% |
| 2005 Q2 | 658.75 Thousand USD | 302.26% |
| 2005 Q3 | 772.37 Thousand USD | 17.25% |
| 2005 Q4 | -1.26 Million USD | -263.27% |
| 2005 Q1 | -325.7 Thousand USD | 58.5% |
| 2005 FY | -143.79 Thousand USD | -114.84% |
| 2004 Q3 | -499.52 Thousand USD | -166.53% |
| 2004 Q4 | -784.79 Thousand USD | -57.11% |
| 2004 FY | 969.1 Thousand USD | -81.49% |
| 2004 Q1 | 1.41 Million USD | 3.59% |
| 2004 Q2 | 750.84 Thousand USD | -46.98% |
| 2003 Q1 | 1.38 Million USD | 62.6% |
| 2003 FY | 5.23 Million USD | 49.74% |
| 2003 Q4 | 1.36 Million USD | 6424.98% |
| 2003 Q3 | 20.95 Thousand USD | -99.11% |
| 2003 Q2 | 2.34 Million USD | 68.88% |
| 2002 FY | 3.49 Million USD | -0.08% |
| 2002 Q4 | 854.67 Thousand USD | 30.66% |
| 2002 Q3 | 654.1 Thousand USD | -43.04% |
| 2002 Q2 | 1.14 Million USD | 29.72% |
| 2002 Q1 | 885.25 Thousand USD | -16.33% |
| 2001 Q1 | 1.08 Million USD | 185.39% |
| 2001 FY | 3.49 Million USD | 34.96% |
| 2001 Q4 | 1.05 Million USD | 99.52% |
| 2001 Q3 | 530.3 Thousand USD | -38.5% |
| 2001 Q2 | 862.23 Thousand USD | -20.42% |
| 2000 Q2 | 1.14 Million USD | -7.38% |
| 2000 Q1 | 1.23 Million USD | 54.28% |
| 2000 FY | 2.59 Million USD | -34.13% |
| 2000 Q4 | -1.26 Million USD | -182.84% |
| 2000 Q3 | 1.53 Million USD | 33.44% |
| 1999 Q4 | 803.2 Thousand USD | -37.92% |
| 1999 Q2 | 1.08 Million USD | 48.89% |
| 1999 Q1 | 728.96 Thousand USD | -43.89% |
| 1999 FY | 3.93 Million USD | 188.36% |
| 1999 Q3 | 1.29 Million USD | 19.21% |
| 1998 FY | 1.36 Million USD | -30.25% |
| 1998 Q4 | 1.29 Million USD | 210.19% |
| 1998 Q2 | 136.13 Thousand USD | -88.63% |
| 1998 Q1 | 1.19 Million USD | 0.0% |
| 1998 Q3 | -1.17 Million USD | -966.16% |
| 1997 Q3 | 283.88 Thousand USD | -56.54% |
| 1997 FY | 1.95 Million USD | 88.37% |
| 1997 Q2 | 653.16 Thousand USD | 128.28% |
| 1997 Q1 | 286.12 Thousand USD | 0.0% |
| 1996 FY | 1.03 Million USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Aurora Cannabis Inc. | -46.45 Million CAD | 77.722% |
| Avicanna Inc. | -7.93 Million CAD | -30.455% |
| Avant Brands Inc. | -1.45 Million CAD | -613.232% |
| Cardiol Therapeutics Inc. | -29.78 Million CAD | 65.255% |
| Crescita Therapeutics Inc. | -1.95 Million CAD | -429.09% |
| Knight Therapeutics Inc. | -2.89 Million CAD | -258.097% |
| MediPharm Labs Corp. | -18.25 Million CAD | 43.299% |
| OrganiGram Holdings Inc. | -242.73 Million CAD | 95.737% |
| Canopy Growth Corporation | -228.71 Million CAD | 95.475% |
| Willow Biosciences Inc. | -13.18 Million CAD | 21.491% |
| Auxly Cannabis Group Inc. | -19 Million CAD | 45.546% |